A Study of Amivantamab and FOLFIRI Versus Cetuximab/?Bevacizumab and FOLFIRI in Participants With KRAS/?NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy (OrigAMI-3)